 (BrJ Ophthalmol 1994; 78: 933-938) 
The term retinitis pigmentosa Genomic DNA was extracted from 20 ml whole blood using a method based on that described by Kunkel. '8 Five different sequence changes were detected, three of which were in designated dominant families. The fourth and fifth changes occur in unclassified families (Fig 1) .
The first sequence change has been reported '9 and occurs in a dominant family from the Tayside/Grampian region (referred to as adRP3 in Lester et al20) with a diffuse form of the Sequence changes were detected using SSCP analysis2' followed by direct sequencing.22 SSCP primers were designed to amplify the whole coding region of the rhodopsin gene and [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] bp of the intron/exon junctions and amplification products were electrophoresed in 5% nondenaturing acrylamide gels (with 5% glycerol at both 5°C and 20°C). Samples which displayed a mobility shift were amplified again using primers upstream of each sense and antisense primer, enabling the whole region under SSCP analysis to be sequenced.
Results SSCP shifts were detected in exons 1, 2, 3, and 5 ofthe rhodopsin gene in five distinct families. No mobility shifts were identified in the isolated cases. Sequencing revealed the shift in exon 1 (Fig 2A) to originate from the heterozygous base substitution ACG to ATG (threonine to methionine) in codon 17 of the rhodopsin gene. The sequence change is shown in Figure 2B next to the normal sequence. This mutation was observed in two affected individuals in two generations of this family (B-6183), but was absent from an unaffected member. In addition, 
CO
group.bmj.com on June 6, 2017 -Published by http://bjo.bmj.com/ Downloaded from the mutation has been observed in other families with adRP2324 and is therefore believed to be responsible for the phenotype.
The shift in exon 2 was observed in one individual, belonging to the family F-6246. The SSCP shift is shown in Figure 3A and sequencing revealed a heterozygous base substitution in codon 135: CGG (arginine) to TGG (tryptophan). The change is shown in Figure 3B . Although this sequence change has only been identified in one individual in an unclassified family, it is likely to be the responsible mutation, as it has previously been reported in dominant RP. 24 The shift in exon 3 was observed in an affected member of the family designated adRP3 and found to be due to a base substitution in codon 178 (TAC (tyrosine) to TGC (cysteine) results not shown). This mutation abolishes a Rsal restriction site and restriction analysis shows the segregation of the mutation with the phenotype as reported previously."9
Two different mobility shifts were observed near exon 5 ofthe rhodopsin gene. The two shifts are shown in Figure 4A . The shift shown in lane 1 was due to a heterozygous G to A substitution at position 5299 in the 3' untranslated region (3'UTR) ofthe gene. This mutation was detected in an affected individual of family K-6056 and is shown in Figure 4B . The shift in lane 2 was due to a heterozygous G to A (AG to AA) substitution at the 3' acceptor site of intron 4 and was observed in three affected family members of family M-6191. The sequence is shown in Figure  4C . Normal sequence at these points are shown alongside as a comparison.
Discussion

RHODOPSIN MUTATIONS IN RP
The mutations identified in exons 1, 2, and 3 have all previously been identified in autosomal dominant cases of retinitis pigmentosa2125 and therefore, although the exon 2 mutation in family F-6246 has only been identified in one individual, it is likely to be the causative mutation in that family. Similarly, the mutations identified in exons 1 and 3 are considered responsible for the phenotype in the respective families (B-6183 and adRP3).
The two sequence changes in exon 5 have not been reported previously. The first of these, a G to A substitution at position 5299 (family K-6056) has not been confirmed in any other affected family members owing to the limited availability of additional samples, and it is therefore conceivable that the change is merely a neutral polymorphism. We have screened a panel of 88 control samples (178 alleles) for the presence of this sequence change and have found the change to be absent in this sample population.
However, until it can be shown to segregate with RP in a family it is best considered a (rare) polymorphism. Attempts are under way to locate additional family members to determine the nature of the change.
The novel splice site mutation was observed in three affected siblings and absent in a fourth unaffected sibling of a dominant family" M-6191). Although this mutation has not been confirmed through two generations it is likely that it is the disease specific mutation in the family. The sequence change destroys the conserved 3' splice acceptor site (AG) Clearly, further studies are required to understand the pathogenic effect of these and similar rhodopsin mutations in rod photoreceptors cells and how these changes also affect, in some instances, the cone cells.
Although the pathogenesis of the condition is not fully understood, knowledge of the actual mutation may provide ophthalmologists with a prognosis indicator for specific families. The codon 17 mutation has previously been reported in families with a regional predilection for pigmentary changes3 32 and appears to correlate with a form of the disease having a moderately good prognosis, and the severity of the disease in the families with the codon 135/178 mutations also concur with previous reports.25 33 It is apparent from the above discussion that 
